The Laboratory of Excellence (LabEx) DEVweCAN invites applications for Junior group leader position in immunology in Research Cancer Institutions of Lyon.
More informations: click here
Follow the CRCL news on Twitter!
You are invited to the 1st International Symposium "Immune Responses in Cancer and Infection" jointly organized by the CRCL and the CIRI (International Research Centre in Infectiology), in Lyon, February 13-15 2017 ! For more information: click here
The organizers thanks all the participants and the sponsors and partners of the event. Click here to access the website. Find below a short movie of the event!
Save the date for the 3rd edition in 25-27 September 2017 !
There are several positions available at the CRCL: click here
- A PhD position (LabEx funding) in the lab of C. Caux and JY Blay. Click here
- 1 Technical position is available at the CRCL, in the group of L. Cova in F. Zoulim's lab. Click here
- 2 postdoc positions. The laboratory of Fabien Zoulim on Viral Hepatitis is looking for two candidates to work on two projects focused on the biology of the viral minichromosome and the identification of novel approaches for its degradation. For more informations: click here
- 1 Engineer position. The laboratory of Fabien Zoulim on Viral Hepatitis is looking for an "Ingénieur d'étude" position to work on its « HBV cure » program. For more informations: click here
- 1 technical staff position (2 years) is available in the team of M. Levrero. More information : click here
- A PhD position is available in the lab of F. Zoulim (supervision B. Bartosch). More information : click here
- A Computational Biologist/Immunology position is available in the team of C. Caux and JY Blay. click here
- Other postdoc positions are available in the teams of M. Gabut and J. Marie: click here
Summer break !
The next CRCL/CLB seminar will take place in September. Have a nice summer break !
Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers
25 March 2016
This study involves the team of Patrick Mehlen.
Netrin-1 has been shown to be up-regulated in a fraction of human cancers as a mechanism to allow these tumors to escape the pro-apoptotic activity of some of its main dependence receptors, the UNC5 homologs (UNC5H). Here we identify the V-2 domain of netrin-1 to be important for its interaction with the Ig1/Ig2 domains of UNC5H2. We generate a humanized anti-netrin-1 antibody that disrupts the interaction between netrin-1 and UNC5H2 and triggers death of netrin-1-expressing tumor cells in vitro. We also present evidence that combining the anti-netrin-1 antibody with epidrugs such as decitabine could be effective in treating tumors showing no or modest netrin-1 expression. These results support that this antibody is a promising drug candidate.
PubMed access: click here
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
25 March 2016
This study involves Oliver Hantz, in the CRCL team of Isabelle Chemin and Philippe Merle.
Chronic hepatitis B virus infection is a leading cause of cirrhosis and liver cancer. Hepatitis B virus encodes the regulatory HBx protein whose primary role is to promote transcription of the viral genome, which persists as an extrachromosomal DNA circle in infected cells. HBx accomplishes this task by an unusual mechanism, enhancing transcription only from extrachromosomal DNA templates. Here we show that HBx achieves this by hijacking the cellular DDB1-containing E3 ubiquitin ligase to target the 'structural maintenance of chromosomes' (Smc) complex Smc5/6 for degradation. See full abstract on PuMed.